Novel EGFR-MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib.
Ostlund T, SutraDhar K, Elgazwi SM, Mahnashi M, Kyeremateng J, Iram S, Halaweish F.
Ostlund T, et al.
Drug Dev Res. 2023 Apr;84(2):200-210. doi: 10.1002/ddr.22023. Epub 2022 Dec 9.
Drug Dev Res. 2023.
PMID: 36484285
Lead compounds MMA132 and MMA102 showed 13 and 20 M IC(50) values, respectively against HepG2-R resistant to Erlotinib. These compounds showed cell cycle arrest of the G2 phase up to 54%, and inhibited cell migration of HepG2-R cells up to 48 h. ...Western blot anal …
Lead compounds MMA132 and MMA102 showed 13 and 20 M IC(50) values, respectively against HepG2-R resistant to Erlotinib. These compoun …